-
公开(公告)号：US20140287454A1
公开(公告)日：2014-09-25
申请号：US14240315
申请日：2012-08-22
Applicant: Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
Inventor： Axel Choidas , Bert Klebl , Peter Habenberger , Jan Eickhoff , Roman Thomas , Johannes Heuckmann
IPC: G01N33/50
CPC classification number: G01N33/5011 , C12Q1/6881 , C12Q1/6886 , C12Q2600/106 , G01N2800/52
Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described. Furthermore, a kit useful for carrying out the methods described herein as well as an oligo- or polynucleotide capable of detecting rearrangements in the NUT gene are provided.
Abstract translation: 本发明涉及一种选择（a）对选择性CDK9抑制剂具有易感性的细胞，（a）组织或（a）细胞培养物的方法。 本文还描述了确定哺乳动物肿瘤细胞或癌细胞对用选择性CDK9抑制剂进行治疗的反应性的方法。 特别地，本发明提供了用于鉴定对选择性CDK9抑制剂敏感的患者或患者的体外方法，由此患者怀疑患有NUT中线癌（NMC）。 本发明还涉及监测或预测NUT中线癌（NMC）治疗功效的方法，其中特别设想用选择性CDK9抑制剂进行治疗。 还描述了在NUT基因中具有至少一个重排的（转基因）非人动物或（转基因）细胞用于筛选和/或验证用于治疗NUT中线癌（NMC）的药物的用途。 此外，提供了可用于实施本文所述方法的试剂盒以及能够检测NUT基因重排的寡核苷酸或多核苷酸。
-
公开(公告)号：US20110257207A1
公开(公告)日：2011-10-20
申请号：US13105957
申请日：2011-05-12
Applicant: Alexander BACKES , Joachim VOGT , Peter AMON , Igor IVANOV , Stefan HANNUS , Matthias BORGMANN , Kerrin HANSEN , Rebecca CASAUBON , Chase SMITH , Krishna MURTHI , Arthur KLUGE , Andreas SCHOOP , Lars NEUMANN , Jan EICKHOFF
Inventor： Alexander BACKES , Joachim VOGT , Peter AMON , Igor IVANOV , Stefan HANNUS , Matthias BORGMANN , Kerrin HANSEN , Rebecca CASAUBON , Chase SMITH , Krishna MURTHI , Arthur KLUGE , Andreas SCHOOP , Lars NEUMANN , Jan EICKHOFF
IPC: A61K31/519 , A61P35/00 , C07D471/04
CPC classification number: C07D471/04
Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are inhibitors or kinases such as Raf, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.
Abstract translation: 本发明提供吡啶并[2,3-d]嘧啶-7-酮的衍生物。 这些化合物是抑制剂或激酶如Raf，包括显示抗增殖活性的化合物，包括抗肿瘤细胞，并且可用于治疗包括癌症在内的疾病。
-
公开(公告)号：USD603870S1
公开(公告)日：2009-11-10
申请号：US29313432
申请日：2009-01-06
Applicant: Kurt Mehnert , Jan Eickhoff
Designer： Kurt Mehnert , Jan Eickhoff
-
公开(公告)号：USD603343S1
公开(公告)日：2009-11-03
申请号：US29313431
申请日：2009-01-06
Applicant: Kurt Mehnert , Jan Eickhoff
Designer： Kurt Mehnert , Jan Eickhoff
-
公开(公告)号：US20070257035A1
公开(公告)日：2007-11-08
申请号：US10589319
申请日：2004-04-07
Applicant: Manfred Berndt , Jose-Angel Mora-Fillat , Jan Eickhoff
Inventor： Manfred Berndt , Jose-Angel Mora-Fillat , Jan Eickhoff
IPC: B65D51/16
CPC classification number: B01L3/50853 , B01L2300/044 , B01L2300/049 , B01L2300/0829 , B01L2400/0638 , B01L2400/065 , Y10T137/9247
Abstract: A cover for sealing a container and preferably containers for a well plate. The cover is comprised of at least a top layer and a bottom layer structured in a way to form a recloseable aperture. Preferably, each of the layers comprise a recloseable aperture structured as flap, damper, baffle or butterfly valve respectively, wherein the recloseable apertures are arranged on top of each other. In a preferred embodiment of the invention a third movable layer is arranged between the top and the bottom layer. By moving the middle layer, the aperture in the cover can be closed.
Abstract translation: 用于密封容器并且优选用于井板的容器的盖。 该覆盖物由至少一层顶层和一底层构成，以形成可再封闭孔。 优选地，每个层包括分别构造为折翼，阻尼器，挡板或蝶阀的可再封闭的孔，其中可再封闭的孔布置在彼此的顶部。 在本发明的优选实施例中，第三可移动层设置在顶层和底层之间。 通过移动中间层，可以关闭盖子中的孔。
-
Patent Agency Ranking
公开(公告)号：US08999982B2
公开(公告)日：2015-04-07
申请号：US13819560
申请日：2011-08-26
Applicant: Carsten Schultz-Fademrecht , Bert Klebl , Axel Choidas , Uwe Koch , Jan Eickhoff , Alexander Wolf , Axel Ullrich
Inventor： Carsten Schultz-Fademrecht , Bert Klebl , Axel Choidas , Uwe Koch , Jan Eickhoff , Alexander Wolf , Axel Ullrich
IPC: A61K31/495 , A61K31/47 , C07D401/12 , C07D401/14 , C07D417/12 , C07D417/14 , C07D413/12 , C07D413/14 , C07D215/233
CPC classification number: C07D401/12 , A61K31/47 , A61K31/495 , C07D215/233 , C07D401/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
Abstract translation: 本发明涉及1-氮杂环-2-甲酰胺和/或其药学上可接受的盐，这些衍生物用作药物活性剂，特别是用于治疗和/或预防Axl受体酪氨酸激酶亚家族诱导的病症，包括 癌症和原发性肿瘤转移，以及含有至少一种所述1-氮杂环-2-甲酰胺衍生物和/或其药学上可接受的盐的药物组合物。
-
公开(公告)号：US20140018365A1
公开(公告)日：2014-01-16
申请号：US13819560
申请日：2011-08-26
Applicant: Carsten Schultz-Fademrecht , Bert Klebl , Axel Choidas , Uwe Koch , Jan Eickhoff , Alexander Wolf , Axel Ullrich
Inventor： Carsten Schultz-Fademrecht , Bert Klebl , Axel Choidas , Uwe Koch , Jan Eickhoff , Alexander Wolf , Axel Ullrich
IPC: C07D401/12 , C07D215/233 , C07D417/12 , C07D413/14 , C07D417/14 , C07D401/14
CPC classification number: C07D401/12 , A61K31/47 , A61K31/495 , C07D215/233 , C07D401/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
Abstract translation: 本发明涉及1-氮杂环-2-甲酰胺和/或其药学上可接受的盐，这些衍生物用作药物活性剂，特别是用于治疗和/或预防Axl受体酪氨酸激酶亚家族诱导的病症，包括 癌症和原发性肿瘤转移，以及含有至少一种所述1-氮杂环-2-甲酰胺衍生物和/或其药学上可接受的盐的药物组合物。
-
公开(公告)号：US20070071638A1
公开(公告)日：2007-03-29
申请号：US11603404
申请日：2006-11-22
Applicant: Karsten Kraiczek , Bernd Glatz , Patrick Mueller , Jan Eickhoff , Martin Baeuerle , Herbert Anderer
Inventor： Karsten Kraiczek , Bernd Glatz , Patrick Mueller , Jan Eickhoff , Martin Baeuerle , Herbert Anderer
IPC: G01N21/00
CPC classification number: G01N30/466 , B01L3/5025 , B01L3/502738 , B01L2400/0622 , G01N30/20 , G01N30/6095 , G01N30/724 , G01N2030/085 , G01N2030/201 , G01N2030/202 , H01J41/04 , H01J49/04
Abstract: A microfluidic chip with at least one inlet port, with at least one microfluidic flow path coupled to the inlet port, and with at least one analytical element adapted for analyzing and/or separating components of a liquid within the flow path which is arranged within or adjacent to, and/or is coupled to the microfluidic flow path. The microfluidic chip is adapted to execute at least two processes in parallel.
Abstract translation: 具有至少一个入口端口的微流体芯片，其具有耦合到入口端口的至少一个微流体流动路径，以及适于分析和/或分离流路内部的液体的组分的至少一个分析元件， 邻近和/或耦合到微流体流动路径。 微流控芯片适于并行执行至少两个过程。
-
公开(公告)号：US09242937B2
公开(公告)日：2016-01-26
申请号：US14002731
申请日：2012-03-01
Applicant: Gerd Rühter , Peter Nussbaumer , Axel Choidas , Carsten Schulz-Fademrecht , Bert Klebl , Jan Eickhoff
Inventor： Gerd Rühter , Peter Nussbaumer , Axel Choidas , Carsten Schulz-Fademrecht , Bert Klebl , Jan Eickhoff
IPC: C07D211/72 , C07D213/74 , A61K31/4418 , A61K45/06
CPC classification number: C07D213/74 , A61K31/4418 , A61K45/06
Abstract: The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.
Abstract translation: 本发明涉及二取代的吡啶衍生物和/或其药学上可接受的盐，这些衍生物作为药物活性剂的用途，特别是用于预防和/或治疗感染性疾病，包括机会性疾病，免疫疾病，自身免疫性疾病，心血管疾病 ，细胞增殖性疾病，炎症，勃起功能障碍和中风，以及含有至少一种所述二取代吡啶衍生物和/或其药学上可接受的盐的药物组合物。 此外，本发明涉及所述二取代的吡啶衍生物作为蛋白激酶的抑制剂的用途。
-
公开(公告)号：US20140296304A1
公开(公告)日：2014-10-02
申请号：US14002731
申请日：2012-03-01
Applicant: Gerd Rühter , Peter Nussbaumer , Axel Choidas , Carsten Schulz-Fademrecht , Bert Klebl , Jan Eickhoff
Inventor： Gerd Rühter , Peter Nussbaumer , Axel Choidas , Carsten Schulz-Fademrecht , Bert Klebl , Jan Eickhoff
IPC: C07D213/74 , A61K45/06 , A61K31/4418
CPC classification number: C07D213/74 , A61K31/4418 , A61K45/06
Abstract: The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.
Abstract translation: 本发明涉及二取代的吡啶衍生物和/或其药学上可接受的盐，这些衍生物作为药物活性剂的用途，特别是用于预防和/或治疗感染性疾病，包括机会性疾病，免疫疾病，自身免疫性疾病，心血管疾病 ，细胞增殖性疾病，炎症，勃起功能障碍和中风，以及含有至少一种所述二取代吡啶衍生物和/或其药学上可接受的盐的药物组合物。 此外，本发明涉及所述二取代的吡啶衍生物作为蛋白激酶的抑制剂的用途。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.018 seconds)
